GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer

Trial Profile

GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms GALADON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Dec 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database
    • 18 Jun 2015 Planned End Date changed from 1 Sep 2019 to 1 Sep 2022, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top